Hospitalization for Lower Respiratory Tract Disease in Preterm Infants: Effects of Prophylaxis with Palivizumab

Giacomo Faldella, R. Alessandroni, G. Aquilano, S. Vandini, M. Lanari, M. Silvestri, A. Pistorio, G. A. Rossi

Research output: Contribution to journalArticle

Abstract

To evaluate the effect of palivizumab prophylaxis on hospitalization for acute respiratory tract infections (RTI) in preterm infants, a prospective study was performed on a cohort of preterm infants [gestational age (GA) ≤32weeks], admitted at birth to a Neonatology Intensive Care Unit (NICU) (follow-up: 30-month after discharge). 154 palivizumab-recipients and 71 palivizumab-non-recipients were evaluated. During follow-up, a similar rate of hospitalization for RTI was found in the two groups (11.3% in palivizumab-non-recipients and 15.58% in palivizumab-recipients, P=0.39). However, when only infants hospitalized during their first respiratory syncytial virus (RSV) epidemic season and with a chronological age

Original languageEnglish
Pages (from-to)30-35
Number of pages6
JournalJournal of Chemotherapy
Volume22
Issue number1
Publication statusPublished - Feb 2010

    Fingerprint

Keywords

  • Admitting department
  • Hospital
  • Palivizumab
  • Preterm birth
  • Respiratory syncytial virus

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Pharmacology (medical)
  • Pharmacology

Cite this

Faldella, G., Alessandroni, R., Aquilano, G., Vandini, S., Lanari, M., Silvestri, M., Pistorio, A., & Rossi, G. A. (2010). Hospitalization for Lower Respiratory Tract Disease in Preterm Infants: Effects of Prophylaxis with Palivizumab. Journal of Chemotherapy, 22(1), 30-35.